+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ainos Inc (AIMD) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 42 Pages
  • April 2023
  • GlobalData
  • ID: 5680618
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Ainos Inc (AIMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ainos Inc (Ainos), formerly Amarillo Biosciences Inc, develops biologics for the treatment of human and animal diseases. It develops innovative therapeutic candidates for the treatment of diseases such as influenza, hepatitis C, thrombocytopenia, neoplastic, viral diseases, autoimmune disorders and other indications using its core technology (proprietary low dose form) of natural human interferon alpha. Its product portfolio includes COVID-19 point-of-care test such as antigen rapid test, molecular rapid test and VOC-based point-of-care. The company primarily operates in the US and supplies its product and medical equipment in Taiwan, People's Republic of China, Hong Kong through its branches and provides food supplements and nutraceuticals in the Asian markets. Ainos is headquartered in San Diego, California, the US.

Ainos Inc Key Recent Developments

  • Mar 31, 2023: Ainos reports fourth quarter and full year 2022 financial results
  • Aug 15, 2022: Ainos reports second quarter 2022 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Ainos Inc - Key Facts
  • Ainos Inc - Key Employees
  • Ainos Inc - Key Employee Biographies
  • Ainos Inc - Major Products and Services
  • Ainos Inc - History
  • Ainos Inc - Company Statement
  • Ainos Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Ainos Inc - Business Description
  • R&D Overview
  • Ainos Inc - Corporate Strategy
  • Ainos Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ainos Inc - Strengths
  • Ainos Inc - Weaknesses
  • Ainos Inc - Opportunities
  • Ainos Inc - Threats
  • Ainos Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Ainos Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Ainos Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Ainos Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 31, 2023: Ainos reports fourth quarter and full year 2022 financial results
  • Aug 15, 2022: Ainos reports second quarter 2022 financial results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Ainos Inc, Key Facts
  • Ainos Inc, Key Employees
  • Ainos Inc, Key Employee Biographies
  • Ainos Inc, Major Products and Services
  • Ainos Inc, History
  • Ainos Inc, Other Locations
  • Ainos Inc, Key Competitors
  • Ainos Inc, Ratios based on current share price
  • Ainos Inc, Annual Ratios
  • Ainos Inc, Interim Ratios
  • Ainos Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Ainos Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Ainos Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Ainos Inc, Performance Chart (2018 - 2022)
  • Ainos Inc, Ratio Charts
  • Ainos Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Ainos Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanofi-Aventis US LLC
  • Regeneron Pharmaceuticals Inc
  • Novo Nordisk Inc
  • InterMune Inc
  • Hoffmann-La Roche Inc
  • AIM ImmunoTech Inc